ArticlePloS one2025
Computational prediction of the pathogenic variants of arachidonate 5-lipoxygenase activating protein using Molecular Dynamics simulation.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated transcriptomic, proteomic, and metabolomic analyses reveal molecular mechanisms underlying clutch length differences in goose ovaries.Poultry science · 2026Article
- Identification of novel genomic variants in diabetic nephropathy patients using whole-exome sequencing: a pilot investigation.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The arachidonate 5-lipoxygenase activating protein (ALOX5AP) regulates leukotrienes (LTs) synthesis. LTs are involved in inflammation which is implicated in cardiovascular diseases (CVDs) and stroke. Variations in ALOX5AP gene are associated with CVDs, stroke and others because of their possible effects on ALOX5AP stability and function. In this study we investigated with molecular dynamics (MD) simulation the structural impacts of L12F, A56V, G75R, and G87R variants on ALOX5AP. We employed an array of bioinformatics techniques, including SIFT, PolyPhen-2, PANTHER, SNPs&GO, PhD-SNP, i-Mutant, MuPro, MutPred, ConSurf, and GROMACS. Results showed that the L12F variant increased structural compactness, as indicated by diminished solvent accessibility, a reduced radius of gyration, and a decrease in hydrogen bonding capacity. The A56V variant destabilized the ALOX5AP, demonstrating elevated root mean square deviation (RMSD), augmented solvent-accessible surface area, and diminished ALOX5AP compactness. The G75R and G87R variants exhibited mild effects on ALOX5AP wildtype. However, simulation trajectory snapshots results indicated G75R and G87R variants induce instability leading to structural perturbations of ALOX5AP probably due to the charge of arginine introduced by the G75R and G87R mutation. The G75R and G87R variants potentially influence ALOX5AP dynamics, stability, and function. These results require further verification in future case-control and protein functional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.